Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

234 Views

Poster Session: HIV: Treatment

1283 - Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

David A. Margolis, MD MPH

Head of Infectious Diseases Therapy Area
Brii Biosciences
Durham, NC, United States

Co-Author(s)

JM

Ji Ma, PhD

Brii Biosciences
San Mateo, California, United States
MW

Michael Watkins, PharmD

Brii Biosciences
Durham, North Carolina, United States
YW

Yujin Wang, M.Sc.

Brii Biosciences
San Mateo, California, United States
CT

Chetana Trivedi, B.A.

Brii Biosciences
Durham, North Carolina, United States
XW

Xuelian Wei, PhD

Brii Biosciences
San Mateo, California, United States
LZ

Lijie Zhong, PhD

Brii Biosciences
San Mateo, California, United States
KP

Kamlesh Patel, PhD

Brii Biosciences
Durham, North Carolina, United States
LY

Li Yan, MD PhD

Brii Biosciences
Philadelphia, Pennsylvania, United States
ZH

Zhi Hong, PhD

Brii Biosciences
Durham, North Carolina, United States
JG

Jean-Luc Girardet, PhD

Brii Biosciences
San Diego, California, United States
LX

Lianhong Xu, PhD

Brii Biosciences
San Mateo, North Carolina, United States